Protalix BioTherapeutics, Inc. (AMEX:PLX)
| CAPS Rating |
|
|---|---|
| Open | $6.43 |
| Previous Close | $6.50 |
| Daily Range | $6.38 - $6.52 |
| 52-Week Range | $4.06 - $9.84 |
| Market Cap | $547.74M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 80,395 |
| Average Daily Volume | 0 |
PLX
VS S&P 500 (SPY)
How do you think PLX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
PLX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
PLX News and Commentary
- As the Biotech Saying Goes... – The Motley Fool
- 3 Stocks to Get on Your Watchlist – The Motley Fool
- Company News for December 7, 2011 - Corporate Summary – NASDAQ
- Protalix BioTherapeutics Shares Got Crushed: What You Need to Know – The Motley Fool
- Regeneron Wins FDA Approval for Eye Drug: 3 Companies Up For Approval – NASDAQ
- 7 Biotechs Near 52-Week Lows – The Motley Fool
- Biotech Winners of a Repatriation Holiday – The Motley Fool
- 2 Backdoor Biotech IPOs to Watch – The Motley Fool
- Pay Attention to Shire – The Motley Fool
- Biotech: Top 3 Analyst Picks – SeekingAlpha
- 14 Small Caps With 2 or More Analyst Downgrades in March – SeekingAlpha
- 5 Stocks Near Lows Seeing Significant Short Covering – SeekingAlpha
- These Companies Don't Care About You – The Motley Fool
- Niche Opportunity May Be Slipping From Protalix's Grasp – SeekingAlpha
- Top 30 Most Undervalued, Underperforming Stocks – SeekingAlpha
- Rare Diseases, Big Opportunity – The Motley Fool
- The Prospects for Protalix Still Look Pretty Good – SeekingAlpha
- 5 of Last Week's Biggest Losers – The Motley Fool
- 22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12 – SeekingAlpha
- What's Next for Protalix BioTherapeutics Shares Fall After FDA CRL? – SeekingAlpha
RSS Headlines
Fool UK
